

jc853 U.S. PTO
04/11/01Please type a plus sign (+) inside this box → +Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCEA
BOX-500

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. 6356.US.P4

First Inventor or Application Identifier J. Henkin, et al.

Title PEPTIDE ANTIANGIOGENIC DRUPS

Express Mail Label No. EL384171800US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. Specification [Total Pages 180]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. Drawing(s) (35 U.S.C. 113) [Total Sheets]
4. Oath or Declaration [Total Pages 3]
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)
 - i. DELETION OF INVENTOR(S)
 - Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

NOTE FOR ITEMS 1 & 13 IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).
ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

5. Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. Computer Readable Copy
 - b. Paper Copy (identical to computer copy)
 - c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. Assignment Papers (cover sheet & document(s))
8. 37 C.F.R. § 3.73(b) Statement Power of
(when there is an assignee) Attorney
9. English Translation Document (if applicable)
10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS
Citations
11. Preliminary Amendment
12. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
13. * Small Entity Statement(s) Statement filed in prior application
(PTO/SB/09-12) Status still proper and desired
14. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
15. Other: Express Mail Certificate.....

16. If a CONTINUATING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment.

 Continuation Divisional Continuation-in-part (CIP) of prior application No: 09/447,226

Prior application information: Examiner Moezie, F.

Group / Art Unit: 1653

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.
17. CORRESPONDENCE ADDRESS
 Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or Correspondence address below

Name	Steven F. Weinstock		
	Abbott Laboratories		
Address	Dept. 377 Bldg. AP6D-2		
	100 Abbott Park Road		
City	Abbott Park	State	IL
Country	United States of America	Telephone	(847) 937-0042
			Fax (847) 938-2623

Name (Print/Type)	Gregory W. Steele	Registration No. (Attorney/Agent)	33,796
Signature			
		Date	5/11/01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

JC997 U.S. PRO
09/833196

04/11/01

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 1999

Patent fees are subject to annual revision.

Small Entity payments must be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

TOTAL AMOUNT OF PAYMENT (\$ 710.00)

Complete if Known

Application Number	
Filing Date	April 11, 2001
First Named Inventor	Jack Henkin
Examiner Name	
Group / Art Unit	
Attorney Docket No.	6356.US.P4

METHOD OF PAYMENT (check one)

The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number
01-0025
Deposit Account Name

Charge Any Additional Fee Required Under
37 CFR 1.16 and 1.17

Payment Enclosed:
 Check Money Order Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101	201	380 Utility filing fee	710.00
106	310	206 155 Design filing fee	
107	480	207 240 Plant filing fee	
108	760	208 380 Reissue filing fee	
114	150	214 75 Provisional filing fee	

SUBTOTAL (1) (\$ 710.00)

2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid
12	-20**=0	X 0	=
Independent Claims 2	-3**=0	X	=
Multiple Dependent			= 0.00

**or number previously paid, if greater; For Reissues, see below

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103	18	203 9 Claims in excess of 20
102	78	202 39 Independent claims in excess of 3
104	260	204 130 Multiple dependent claim, if not paid
109	78	209 39 ** Reissue independent claims over original patent
110	18	210 9 ** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 0.00)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105	130	205 65 Surcharge - late filing fee or oath	0.00
127	50	227 25 Surcharge - late provisional filing fee or cover sheet	0.00
139	130	139 130 Non-English specification	0.00
147	2,520	147 2,520 For filing a request for reexamination	0.00
112	920*	112 920* Requesting publication of SIR prior to Examiner action	0.00
113	1,840*	113 1,840* Requesting publication of SIR after Examiner action	0.00
115	110	215 55 Extension for reply within first month	0.00
116	380	216 190 Extension for reply within second month	0.00
117	870	217 435 Extension for reply within third month	0.00
118	1,360	218 680 Extension for reply within fourth month	0.00
128	1,850	228 925 Extension for reply within fifth month	0.00
119	300	219 150 Notice of Appeal	0.00
120	300	220 150 Filing a brief in support of an appeal	0.00
121	260	221 130 Request for oral hearing	0.00
138	1,510	138 1,510 Petition to institute a public use proceeding	0.00
140	110	240 55 Petition to revive - unavoidable	0.00
141	1,210	241 605 Petition to revive - unintentional	0.00
142	1,210	242 605 Utility issue fee (or reissue)	0.00
143	430	243 215 Design issue fee	0.00
144	580	244 290 Plant issue fee	0.00
122	130	122 130 Petitions to the Commissioner	0.00
123	50	123 50 Petitions related to provisional applications	0.00
126	240	126 240 Submission of Information Disclosure Stmt	0.00
581	40	581 40 Recording each patent assignment per property (times number of properties)	0.00
146	760	246 380 Filing a submission after final rejection (37 CFR 1.129(a))	0.00
149	760	249 380 For each additional invention to be examined (37 CFR 1.129(b))	0.00
Other fee (specify) _____			0.00
Other fee (specify) _____			0.00

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0.00)

SUBMITTED BY

Complete (if applicable)

Typed or Printed Name	Gregory W. Steele	Reg. Number	33,796
Signature	<i>[Signature]</i>	Date	4/11/01
		Deposit Account User ID	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	J. Henkin, et al.	Group Art No.:	(not yet assigned)
SERIAL NO.:	(not yet assigned)	Examiner:	(not yet assigned)
FILED:	April 11, 2001		
TITLE:	PEPTIDE ANTIANGIOGENIC DRUGS		
CASE NO.:	6356.US.P4		

EXPRESS MAIL CERTIFICATE


"Express Mail" label number EL384171800US
Date of Deposit April 11, 2001

I hereby state that the following attached papers or fees

1. Utility Patent Application Transmittal, in duplicate
2. Specification (175 pages), Claims (4 pages), Abstract (1 page)
3. Fee Transmittal, in duplicate
4. Sequence Listing
5. Diskette (Sequence Listing)
6. Sequence Statement
7. Information Disclosure Statement
8. Form PTO-1449, in duplicate
9. References as cited on Form PTO-1449 (15 references)
10. Declaration and Power of Attorney (Executed)
11. Return Receipt Postcard

Are being deposited with the United States Postal Service
"Express Mail Post Office to Addressee" service under 37 CFR
1.10, on the date indicated above and is addressed to:

The Assistant Commissioner for Patents
Washington D.C. 20231


Kathleen T. Litz Date

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	J. Henkin, et al.	Express Mail No.: EL384171800UUS
Serial NO.:	(not yet assigned)	I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee Service under 37 C.F.R. 1.10 addressed to:
Filed:	April 11, 2001	Box Patent Application Assistant Commissioner for Patents Washington, D.C. 20231, on:
Title:	PEPTIDE ANTIANGIOGENIC DRUGS	Date of Deposit: April 11, 2001
Case No.:	6356.US.P4	<u>Tanya Benavidez 4/11/01</u> Tanya Benavidez Date
Group Art No.:	(not yet assigned)	
Examiner:	(not yet assigned)	

STATEMENT TO SUPPORT FILINGS AND SUBMISSIONS IN ACCORDANCE WITH
37 C.F.R. §§1.821 THROUGH 1.825

Box Patent Application
Assistant Commissioner for Patents
Washington D.C. 20231

Dear Sir:

The undersigned, being the attorney of record of the above-identified patent application, submits the following statement regarding the Sequence Listing in paper and computer readable form submitted herewith:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted herewith in accordance with C.F.R. §1.821(c) and (e), respectively, are the same.

Respectfully Submitted,
J. Henkin, et al.


Gregory W. Steele
Registration No. 33,796
Attorney for Applicants

ABBOTT LABORATORIES
D-0377/AP6D-2
100 Abbott Park Road
Abbott Park IL 60064-6050
Telephone: (847) 937-0042
Facsimile: (847) 938-2623